Stock Events

Stock Events

Sigyn Therapeutics 

$0.029000
4
-$0.00-6.45% Monday 17:22

Statistics

Day High
0.036
Day Low
0.0326
52W High
5
52W Low
0.01
Volume
80,105
Avg. Volume
20,220
Mkt Cap
46,545
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Nov 4
$8.25
Jul 4
$47.15
Nov 3
$6.80
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

18NovExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
Next
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-3.34MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Cytodyn
CYDY
Mkt Cap315.04M
CytoDyn Inc. focuses on innovative treatments for autoimmune diseases and HIV, which overlaps with Sigyn Therapeutics' focus on therapeutic technologies for sepsis and other inflammatory conditions.
Sorrento Therapeutics
SRNE
Mkt Cap385,896
Sorrento Therapeutics, Inc. works on therapies for cancer, inflammation, and autoimmune diseases, competing in the inflammatory and immune-modulating treatment space.
XBiotech
XBIT
Mkt Cap69.21M
XBiotech Inc. specializes in the discovery and development of monoclonal antibodies for treating various inflammatory conditions, directly competing with Sigyn's approach to treating systemic inflammation.
Incyte
INCY
Mkt Cap25.21B
Incyte Corporation has a broad portfolio in oncology and inflammation, potentially competing in the development of treatments for conditions targeted by Sigyn Therapeutics.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, Inc. offers treatments for inflammatory and immune diseases, directly competing with Sigyn's focus on inflammatory conditions.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, Inc. has a diverse portfolio including treatments for viral diseases, inflammatory, and oncological conditions, overlapping with Sigyn's therapeutic areas.
AMGEN
AMGN
Mkt Cap233.78B
Amgen Inc. has a broad focus on biologics in various therapeutic areas, including inflammation and oncology, which could compete with Sigyn's technology in treating systemic inflammation.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie Inc. focuses on immunology and oncology, with a strong pipeline in anti-inflammatory treatments, potentially competing with Sigyn's therapeutic approach.

About

Sigyn Therapeutics, Inc. operates as a therapeutic technology enterprise currently in its development phase. The company's core innovation is Sigyn Therapy, an advanced blood purification system designed to overcome the limitations of existing drugs and medical devices used to treat severe inflammatory disorders. A key focus is on sepsis, which represents a major cause of hospital-related deaths. Furthermore, Sigyn Therapeutics is actively evaluating the potential of Sigyn Therapy to address a broad spectrum of other therapeutic targets, including bacterial endotoxins, peptidoglycan, and lipoteichoic acid; various viral pathogens; harmful hepatic toxins; CytoVesicles; and significant pro-inflammatory cytokines such as tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6. The company is headquartered in San Diego, California.
Show more...
CEO
James A. Joyce
Employees
4
Country
United States
ISIN
US82674U2050

Listings

OTC Link
US
SIGY

0 Comments

Share your thoughts

FAQ

What is Sigyn Therapeutics stock price today?▼
The current price of SIGY is $0.03 USD — it has decreased by -6.45% in the past 24 hours. Watch Sigyn Therapeutics stock price performance more closely on the chart.
What is Sigyn Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Sigyn Therapeutics stocks are traded under the ticker SIGY.
Is Sigyn Therapeutics stock price growing?▼
SIGY stock has fallen by -6.45% compared to the previous week, the month change is a -17.14% fall, over the last year Sigyn Therapeutics has showed a -99.37% decrease.
What is Sigyn Therapeutics market cap?▼
Today Sigyn Therapeutics has the market capitalization of 46,545
When is the next Sigyn Therapeutics earnings date?▼
Sigyn Therapeutics is going to release the next earnings report on November 18, 2026.
What is Sigyn Therapeutics revenue for the last year?▼
Sigyn Therapeutics revenue for the last year amounts to 0 USD.
What is Sigyn Therapeutics net income for the last year?▼
SIGY net income for the last year is -3.34M USD.
Does Sigyn Therapeutics pay dividends?▼
Yes, SIGY dividends are paid en. The last dividend per share was 8.25 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Sigyn Therapeutics have?▼
As of September 04, 2026, the company has 4 employees.
In which sector is Sigyn Therapeutics located?▼
Sigyn Therapeutics operates in the Health & Wellness sector.
When did Sigyn Therapeutics complete a stock split?▼
The last stock split for Sigyn Therapeutics was on January 31, 2024 with a ratio of 1:40.
Where is Sigyn Therapeutics headquartered?▼
Sigyn Therapeutics is headquartered in San Diego, United States.